Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study

Go back to Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study
(NASDAQ: ENSC) Delayed: 0.60 +0.04 (7.14%)
Previous Close $0.56    52 Week High $ 
Open $0.56    52 Week Low $ 
Day High $0.60    P/E N/A 
Day Low $0.55    EPS $ 
Volume 332,920